NCT00735787 - Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Psoriasis

Interventions

BIOLOGICAL

Placebo

Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.

BIOLOGICAL

Adalimumab

Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.

Trial Locations (17)

31217

Site Reference ID/Investigator# 10003, Macon

63117

Site Reference ID/Investigator# 10171, St Louis

72205

Site Reference ID/Investigator# 10168, Little Rock

77030

Site Reference ID/Investigator# 11302, Houston

78258

Site Reference ID/Investigator# 10166, San Antonio

93309

Site Reference ID/Investigator# 10005, Bakersfield

08520

Site Reference ID/Investigator# 10164, East Windsor

75246-1613

Site Reference ID/Investigator# 10173, Dallas

T5K 1X3

Site Reference ID/Investigator# 10180, Edmonton

V5Z 4E8

Site Reference ID/Investigator# 10169, Vancouver

B3H 1Z4

Site Reference ID/Investigator# 10170, Halifax

L8N 1V6

Site Reference ID/Investigator# 10179, Hamilton

N5X 2P1

Site Reference ID/Investigator# 10004, London

P1B 3Z7

Site Reference ID/Investigator# 10177, North Bay

N2J 1C4

Site Reference ID/Investigator# 10175, Waterloo

H2K 4L5

Site Reference ID/Investigator# 10165, Montreal

G1V 4X7

Site Reference ID/Investigator# 10176, Québec